Investigating RNF43 Mutations as Biomarkers for ctDNA Surveillance of Colorectal Cancer by Lima, Jordon Shae





Investigating RNF43 Mutations as Biomarkers for 




A thesis submitted in partial fulfilment of the Degree of 
Bachelor of Biomedical Sciences with Honours. 
University of Otago, Dunedin, New Zealand. 
 
October 2020 
Page | ii  
 
Waerea1 
Parahia te ahunga ka whāia 
Parahia ngā whāwhātanga ka tauhia 
Hīkina te kura huna 
Rongohia te maruwehi 
Tomokia te marau kai te aro 
Kia iti ko te rahi 
Ko te waerea kia wātea 
Āe, kua wātea. 
 
Blessing 
Clear the pathway to be followed 
Make free from obstruction the tasks to be undertaken 
Hold up on high this prized knowledge 
And pay reverence to it 
As we delve into the subject that is before us 
Let us be humble 
The incantation to make free from restriction 
Indeed, it has been freed.  
 
1 This waerea and its English translation were created by Mr. Neihana Matiu and Dr. Karyn Paringatai to protect 
the knowledge contained within this thesis, those that have collected it, and those that will use it. 
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ABSTRACT 
This project aimed to investigate the utility of RNF43 mutations for circulating tumour DNA 
(ctDNA) surveillance of colorectal cancer (CRC). CRC is the second deadliest cancer in New 
Zealand. CRC patients currently under-go 5 years of follow-up surveillance post-resection of 
primary tumours, requiring CT scans, colonoscopies, and CEA-tests to detect disease 
recurrences. These methods can be invasive, difficult to access, and inaccurate. Surveillance 
with ctDNA during and after treatment is a promising alternative to these current methods. 
ctDNA is DNA released into the bloodstream by dying tumour cells. It carries tumour-
specific information such as somatic mutations and methylation changes that distinguish it 
from normal cell-free DNA in the bloodstream. ctDNA can be detected and quantified in 
patient plasma samples via assays for these tumour-specific alterations. ctDNA levels have 
been shown to correlate with tumour burden, disease progression, risk of recurrence, and real-
time response to treatment.  
RNF43 is a tumour suppressor that plays an important role in regulating the Wnt signalling 
pathway that is frequently dysregulated in CRC. We investigated RNF43 mutations in a New 
Zealand CRC patient cohort to determine if they occur at a high enough frequency to justify 
their inclusion on custom targeted tumour sequencing panels being developed for the 
detection of personalised mutation markers for ctDNA surveillance of CRC.  
In this project, we designed a novel protocol for sequencing RNF43 that optimises time and 
cost efficiencies and yields highly accurate exome sequence data to identify true pathogenic 
mutations. Using this protocol, we identified pathogenic mutations in RNF43 in 3 of 24 
(~13%) primary tumour samples. This fairly high mutation rate and the likely founder status 
of the pathogenic RNF43 mutations justifies the inclusion of the RNF43 gene in targeted 
sequencing panels for the routine detection and quantification of ctDNA markers in CRC.  
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1 INTRODUCTION 
Ahakoa he iti te matakahi, ka pakaru i a ia te tōtara.3 
1.1 USE OF WHAKATAUKĪ 
It is important to contextualise the writing style I have chosen for this thesis so readers can 
understand the motivations behind it. I wrote this thesis with the intention that whakataukī 
(Māori proverbial sayings) would guide the structure of the chapters they head. Footnotes 
have been included to provide an English translation, as I wish to provide every reader with 
the opportunity to understand the overtones for each chapter. Use of both Māori and English 
also reflects both my Māori and Pākehā identities – as they are one. 
Whakataukī have also been used in this context to demonstrate that Te Ao Māori and 
Academia are not the opposite worlds they are historically portrayed as. Incorporation of both 
‘worlds’ in the written collection of my work was important to me as my commitment to both 
cancer research and Te Ao Māori is almost entirely personal. I have felt the loss of my culture 
due to being raised outside of my tribal area, despite identifying as Māori and constantly 
being judged as such. I have also felt the loss of my family and friends due to cancer – a 
disease that offers more confusion than clarity. While completing this thesis, I have gained an 
understanding of both of these complex topics, with my personal investments in one driving 
the other. I believe these personal investments, as well as being a Kaupapa Māori researcher, 
makes these reflections integral to the work undertaken for this project and to health research 
as a whole. 
 
3 Even though the wedge is small, it brings down the mighty totara tree. 
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1.2 COLORECTAL CANCER 
Colorectal cancer (CRC) is the third most common cancer in the world and the fourth greatest 
cause of cancer mortality, with 1,800,977 new cases diagnosed in 2018 and an estimated 
694,000 deaths every year [1]. Most CRC cases and deaths occur in countries with high 
indices of development and/or incomes, with the highest estimated rates occurring in 
Australia and New Zealand, respectively. CRC is the second deadliest cancer in New Zealand 
with over 3,000 diagnoses and 1,200 deaths every year [2].  
Survival rates for CRC are strongly related to the stage of disease at diagnosis. The five-year 
survival rate for localised (Stage 0 & I) CRC is 90% and about 39% of patients are diagnosed 
at this early stage. In comparison, the five-year survival rate for CRC that has spread to 
surrounding tissues (Stage II & III) or distant sites (Stage IV) decreases to 71% and 14% 
respectively [1,3]. Early detection of CRC is improving; however, New Zealand currently has 
the second highest rates of both CRC incidence and mortality in the world and globally, CRC 
is expected to increase in incidence by up to 60% in the next 15 years [1-3].  
Notably, CRC mortality rates are twice as high for New Zealand Māori compared to non-
Māori, despite similar incidence rates in both populations [4]. Māori are also more likely to 
be diagnosed with advanced disease compared to non-Māori [5], reflecting inequitable access 
to early screening and resources for disease prevention and post-treatment follow-up [6]. NZ 
Māori populations face barriers to cancer care primarily due to geographic, socioeconomic, 
and cultural factors [7-10] and similar disparities can also be seen in rural and low-decile 
communities [11]. 
A diagnostic technology that is accessible, highly specific, and able to address deficits in 
healthcare equity for rural and Māori populations will be essential for improving New 
Zealand’s disturbing CRC statistics. 
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1.2.1 MOLECULAR SUBTYPES AND TUMOUR EVOLUTION 
Colorectal tumours arise through a series of complex histological changes driven by genetic 
alterations in oncogenes or tumour suppressor genes. These alterations transform normal 
colonic epithelium into benign growths (more commonly known as polyps), which may 
acquire genetic mutations that convey selective advantages to tumour cells over normal cells 
to develop into malignant tumours over time [12]. This ‘adenoma-carcinoma’ sequence is 
best depicted by Vogelstein et al. (2013), as shown in Figure 1.1. 
The first step in this sequence is most frequently an inactivating mutation in the tumour 
suppressor gene APC, with mutations in driver genes such as p53 occurring later in tumour 
development [13]. Development of a carcinoma has two important features: selection for a 
mutation that promotes initial clonal expansion into an adenoma, and, frequently, occurrence 
of genetic instability to allow for accelerated multiple hits at other genes responsible for 
tumour progression and malignant transformation. Selection for APC mutations confers both 
of these growth advantages due to the important regulatory role APC plays in the Wnt 
signalling pathway. The Wnt signalling pathway and its components were originally 
characterised in CRCs [14]. 
Figure 1.1 Genetic alterations and the progression of colorectal cancer. Genetic 
alterations and the progression of colorectal cancer. The major signalling pathways that 
drive tumourigenesis are shown at the transitions between each tumour stage. One of 
several driver genes that encode components of these pathways can be altered in any 
individual tumour. Patient age (years) indicates the time intervals during which the driver 
genes are usually mutated. [12] 
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The Wnt signalling pathway is highly evolutionary conserved throughout all species [15], 
emphasising the importance of this pathway in organism development. The key interactions 
in this pathway occur between Wnt lipids and the frizzled receptors. Activation of these 
receptors results in an increase in beta-catenin accumulation, which then enters the nucleus to 
promote transcription of target genes. This signal transduction is negatively regulated by an 
E3 ubiquitin ligase complex containing RNF43 and APC proteins that marks frizzled 
receptors, beta-catenin, and other pathway components for proteasomal degradation [16].  
Germline mutations in APC and RNF43 are also associated with the development of polyps in 
familial adenomatous polyposis (FAP) [17] and serrated polyposis syndromes [18], 
respectively. Both are negative regulators of the Wnt pathway. Though the causative nature 
of APC mutations in FAP is well-characterised, RNF43 mutations are less well characterised 
and are only suspected to play a role in severe serrated polyposis syndromes [19]. 
Basic principles of evolution apply to cancer pathogenesis. All of the known mutations in 
driver genes can be classified into one or more ‘hallmark’ of cancer that confers a selective 
growth advantage for cancer cells [20]. These hallmarks are described by Hanahan and 
Weinberg (2011) and involve cancer cell manipulation of six key processes required for 
malignancy, three of which are most important when considering the role of the Wnt 
pathway: cell fate, cell survival, and genome maintenance. Most cellular metabolic pathways 
will be involved in these key processes and due to their highly overlapping nature, one would 
predict that mutations in different pathway components can result in the same selective 
growth advantage for cancer cells. Therefore, mutations in the various components of a single 
pathway would be expected to be mutually exclusive – that is, not occurring in the same 
tumour – and this is the basis of our investigation into the role of RNF43 mutations in the 
Wnt signalling pathway of CRC tumours, particularly in the absence of APC mutations. 
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1.2.2 CURRENT METHODS OF CRC SURVEILLANCE 
The five-year survival rate for patients diagnosed with CRC is proportional to the stage at 
which tumours are diagnosed. Patients diagnosed with advanced or metastatic disease have a 
five-year survival rate of approximately 14% [21]. This places emphasis on the importance of 
routine screening for early detection of disease. In New Zealand, this has been addressed by 
the national bowel screening programme for adults over the age of 60 years. 
In addition to early detection, ongoing surveillance post-treatment to detect early relapse 
plays an important role in increasing overall survival rates for CRC patients. In New Zealand, 
the current standard of care for CRC patients involves routine check-ups 3 to 4 times a year 
for 5-years post-resection of the primary tumour. These routine check-ups require physical 
exams, blood tests, sigmoidoscopies, colonoscopies and CT or PET scans (Table 1.1).  
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Table 1.1 Current clinical follow-up guidelines for patients living with colon and rectal 
cancers in New Zealand post-resection of the primary tumour. 
















 Stage I Stage I1 Stage II Stage III Stage IV 






CEA Test None 3-monthly for 2 years, then 6-monthly 
MRI2 
If CRM <2 mm, consider 6-monthly surveillance for 2 
years, as per MDM recommendation 
Colonoscopy 
Pre-operative or within 12-months of surgery, otherwise 
initial surveillance at 3 years, then 5-yearly, ceasing at 



















1Stage I rectal cancer with perineural invasion. 
2MRI only required for rectal cancers – not colon cancers. 
3Additional 18-month and 2.5-year clinic visits only required for rectal cancers. 
CT = computerised tomography. CEA = carcinoembryonic antigen. CRM = circumferential resection margin. 
MDM = multidisciplinary meeting. 
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Table 1.1 summarises the current clinical follow-up guidelines from the Southern DHB for 
colon and rectal cancer patients in New Zealand. Protocols vary slightly between the two 
cancers, with rectal cancers having additional surveillance procedures (MRI scans, rectal 
examinations, and sigmoidoscopies).  
Currently, the preferred methods for evaluating tumour response to treatment are the 
anatomical imaging techniques computerised tomography (CT) and magnetic resonance 
imaging (MRI) that allow for assessment of changes in tumour diameter [22]. Unfortunately, 
CT scans can be difficult to access, are expensive, and frequency of use is limited due to 
accumulated radiation exposure [23]. 
Routine blood tests for detection of the blood marker carcinoembryonic antigen (CEA) is a 
less invasive, more cost-effective method for monitoring CRC response to treatment and 
development of resistance. However, changes in CEA levels are not highly tumour specific, 
often results in false-positive results following chemotherapy, and are only detectable in 
~60% of cancers [24-26].  It is therefore clear that there is a pressing need for new 
surveillance methods with greater accuracy and accessibility. 
1.3 CIRCULATING TUMOUR DNA 
Circulating tumour DNA (ctDNA) refers to small (~160bp) DNA fragments that are released 
into the bloodstream by tumour cells via necrosis, apoptosis, and active secretion [27]. 
ctDNA is collected via blood sampling and can be distinguished from normal circulating cell-
free DNA (cfDNA) by the tumour-specific alterations they carry, including somatic 
mutations, altered methylation, and DNA instability [28,29]. The short half-life of ctDNA in 
plasma (16 mins to 2 hours) enables the detection of cancer-altered copies to be used as ‘real-
time’ measurements of disease burden [29,30]. 
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ctDNA analyses are likely to be the next step in personalised care for CRC patients [31-34]. 
ctDNA analyses have been shown to be effective post-operative predictors of prognosis, early 
detectors of relapse, and may also act as a measure of a patient’s response to treatment [35-
40]. ctDNA also allows for analysis of individual tumour genomes, which improves: 
monitoring of tumour response to treatment; emergence of secondary mutations associated 
with resistance; intra- and inter-tumour heterogeneity; and clonal evolution during the 
progression of cancers [41,42]. Additionally, ctDNA analyses can also be conducted on 
patient urine or cerebrospinal fluid sample – dependent on cancer type and location [43]. 
These ‘liquid biopsies’ are less invasive, safer, more cost-effective, and have a faster turn-
around time than solid tumour biopsies.  They also have the added advantage of enabling 
sequential resampling for closer monitoring of disease [44]. 
Furthermore, studies have shown that serial ctDNA analyses can reveal recurrence up to 
months ahead of radiological imaging [45] and, theoretically at least, provide some molecular 
characterisation of the entire tumour burden, including multiple metastases. Improvements in 
next-generation sequencing (NGS) and PCR technologies have allowed for precise detection 
of low frequency mutant alleles carried on ctDNA for accurate detection of treatment 
resistant clonal populations and the prescription of more effective therapies [46].  
In a recently published paper from the Cancer Genetics Laboratory (Department of 
Biochemistry, University of Otago, Dunedin, New Zealand), a comparison of ctDNA and 
CEA levels was used to accurately assess chemotherapy response in 30 patients with 
metastatic CRC [47]. This paper had three major findings for the advancement of ctDNA in a 
clinical setting: firstly, detectable levels of ctDNA were found in 97% of patients, compared 
to only 83% of patients who had detectable CEA levels; ctDNA predicted more disease 
progression events than CEA, with ctDNA allowing significantly earlier predictions than 
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CEA when both detected progression; and ctDNA was able to detect clinical relapse 
following curative surgery that showed no evidence of residual disease. Overall, ctDNA was 
able to detect disease progression earlier and more frequently than CEA and was more 
responsive to changes in treatment. ctDNA therefore shows promise as an alternative to CEA 
for CRC surveillance, as well as a promising marker for cancers that do not have established 
blood markers.  
1.3.1 SELECTING BIOMARKERS FOR ctDNA SURVEILLANCE OF CRC 
The best ctDNA markers are founder mutations that initiate disease since these mutations 
would be expected to be present in the entire tumour mass regardless of the selection for new 
mutations. Intra-tumour heterogeneity has long been a concern for technologies that monitor 
changes in the tumour genome landscape [48]. Tracking founder mutations reduces the risk 
that only a subset of the tumour burden will be detected by a tumour ctDNA marker. We 
propose that it is important that the gene sequencing panels that are used to identify or select 
ctDNA markers include as many potential founder genes as possible. This would avoid any 
tumour clones being missed due to evolution and would enable more accurate recording of 
disease burden. 
Confirmed founder mutation genes for CRC include APC and occasionally TP53. BRAF 
mutations are not generally considered to be founder mutations as tumours do not exist with 
only BRAF mutations (although epigenetic alterations may precede BRAF mutations). APC 
contains driver mutations in ~80% of CRCs [49], with mutations in other genes such as 
CTNNB1 and RNF43 likely to drive the remaining 20%.  Of these two, RNF43 is not yet 
routinely included on major commercial CRC sequencing panels (such as the Qiagen CRC 
panel) even though its contribution to tumorigenesis in colorectal cancer has been established 
[49,50]. 
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1.4 THE ROLE OF RNF43 IN CRC 
RNF43 encodes ring finger protein 43 (RNF43), an E3 ubiquitin ligase that negatively 
regulates Wnt signalling pathways by targeting effector proteins and receptors for 
degradation [51]. Mutations in RNF43 have been identified in ~15% of CRCs [52,53] and 
loss-of-function mutations result in dysregulation of the Wnt signalling pathway that 
contributes to colorectal carcinogenesis. However, the founder or driver status of these 
RNF43 mutations has not yet been extensively studied. 
As pictured in Figure 1.2, RNF43 encodes a tumour suppressor protein that negatively 
regulates the Wnt signalling pathway by ubiquitinating frizzled receptors, which marks them 
for degradation by the proteasome. This prevents ligand binding and downstream activation 
of gene transcription for factors involved in pathways controlling cell division and 
determination [55]. 
Figure 1.2 The role of RNF43 in the Wnt signalling pathway [54]. (A) in the absence of 
Wnt, RNF43 inhibits Fzd activity so beta-catenin is degraded. (B) In the presence of 
Wnt, RNF43 is bound by RSPO and cannot inhibit Fzd so beta-catenin accumulates in 
the nucleus and increases transcription of target genes. (C) In the presence of mutations 
in any of the Wnt signalling components (highlighted), beta-catenin mediated gene 
transcription is dysregulated leading to an increase in transcription of target genes. 
Fzd = frizzled receptor. *Indicates mutated pathway component. 
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In this study we aimed to determine the rate of pathogenic RNF43 mutations in a NZ CRC 
cohort to inform the utility of adding such mutations to a custom targeted gene sequencing 
panel for CRC that is in development in the Cancer Genetics Laboratory (Department of 
Biochemistry, University of Otago, Dunedin, New Zealand). We hypothesise that patients 
who do not contain pathogenic APC mutations will benefit from surveillance of pathogenic 
RNF43 mutations.  
Though RNF43 might only play a role in a small percentage of CRCs, it has the potential to 
improve ctDNA technology as a whole. To relate this back to the whakataukī presiding over 
this chapter, RNF43 represents the small wedge that may yet fell the mighty tōtara tree. 
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PROJECT AIMS 
I ore a te tuatara ka puta ki waho4 
1. Develop a novel sequencing protocol to optimise exon coverage and DNA sequencing 
quality for the RNF43 gene. 
2. Determine the frequency of pathogenic RNF43 mutations in a NZ colorectal cancer 
cohort. 
3. Determine the utility of pathogenic RNF43 mutations as ctDNA biomarkers for the 
surveillance of colorectal cancer in a NZ cohort. 
  
 
4 A problem is solved by continuing to find solutions. 
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2 MATERIALS AND METHODS 
Tē tōia, te haumatia.5 
2.1 MATERIALS 
2.1.1 REAGENTS 
10X TAE Buffer – Sigma Aldrich, USA  
Agencourt AMPure XP Beads – Beckman-Coulter, USA 
Agilent DNA High Sensitivity kit – Agilent, USA 
DNA Marker 1 – A&A Biotechnologies, Poland 
Eosin Y Solution – Sigma Aldrich, USA 
FastStart Taq DNA Polymerase – Roche, Switzerland 
FastStart Taq DNA Polymerase PCR buffer (10x conc.) with MgCl2 – Roche, Switzerland 
Gel loading dye purple (6x) – New England BioLabs, USA 
Human Genomic DNA – Roche, Switzerland 
HyAgarose™ LE Agarose, Multi-purpose – HydraGene Co Ltd, USA  
Mayer’s Haematoxylin Solution – Sigma Aldrich, USA  
MiSeq V2 Nano 500 bp Kit – Illumina, USA 
NucleoSpin® Gel and PCR Clean-Up Kit – Macherey-Nagel, Germany 
 
5 Nothing can be achieved without a plan, a workforce, and a way of doing things. 
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PCR Grade Nucleotide Mix – Roche, Switzerland 
Qiagen GeneRead DNA FFPE Kit – Qiagen, Germany 
QIAmp Circulating Nucleic Acid Kit – Qiagen, USA 
Qubit™ dsDNA High Sensitivity Assay Kit – Thermo Fisher Scientific, USA 
UltraPure™ DNAse/RNAse-Free Distilled Water – Thermo Fisher Scientific, USA 
2.1.2 EQUIPMENT 
0.2 mL PCR tube strips PCR clean – Eppendorf, USA 
1.5 mL microtubes – Eppendorf, USA 
5 mL Eppendorf tubes® – Eppendorf, USA 
15 mL and 50 mL Falcon tubes – BD Biosciences, USA 
15 mL centrifuge tubes – Greiner Bio-One, Austria 
Agencourt SPRIPlate 96 Super Magnet Plate – Beckman-Coulter, USA  
Agilent 2100 Bioanalyzer – Agilent, USA 
Cell-Free DNA Collection Tubes® – Roche, Switzerland 
Chip priming station – Agilent, USA 
IKA® Chip Shaker – IKA, China 
C1000 Touch™ Thermal Cycler – Bio-Rad, USA 
Contherm Thermotec 2000 Oven – Contherm Scientific Ltd, New Zealand 
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Digital dry block heater – Thermo Fisher Scientific, USA 
Eppendorf Centrifuge 5810R – Eppendorf, USA 
Fume cupboard – Thermoplastic Engineering Ltd, New Zealand 
Leica HI1210 Water Bath – Bio-Strategy, New Zealand 
Leica RM 2125RT Sectioner – Bio-Strategy, New Zealand 
MiSeq System – Illumina, USA 
Microscope glass slides – Marienfeld, Germany 
PCR ThermalSeal® RT2RR™ – Excel Scientific Ltd, USA 
Qubit™ 2.0 Fluorometer – Thermo Fisher Scientific, USA 
QX200™ AutoDG Droplet Digital PCR System – Bio-Rad, USA 
QX200™ Droplet Reader – Bio-Rad, USA 
Select Spin Plate Centrifuge – Select BioProducts, USA 
2.1.3 SOFTWARE 
Agilent 2100 Bioanalyser Expert Software – Agilent, USA 
Ensembl release 101 (https://asia.ensembl.org/index.html) – European Bioinformatics 
Institute, UK 
Galaxy Australia (https://usegalaxy.org.au/) 
Illumina BaseSpace Sequence Hub – Illumina, USA 
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Multiple Primer Analyser (https://www.thermofisher.com/nz/en/home/brands/thermo-
scientific/molecular-biology/molecular-biology-learning-center/molecular-biology-resource-
library/thermo-scientific-web-tools/multiple-primer-analyzer.html) – Thermo Fisher 
Scientific, USA 
Primer3plus (http://www.bioinformatics.nl/cgi-bin/primer3plus/primer3plus.cgi)  
Primer BLAST (https://www.ncbi.nlm.nih.gov/tools/primer-blast/) – National Centre for 
Biotechnology Information (NCBI), USA 
QuantaSoft Analysis Pro Software – Bio-Rad, USA 
SeqMonk application Version 1.47.0 – Babraham Bioinformatics, UK 
The Human Genomic Variant Search Engine (https://varsome.com/) – Saphetor SA, 
Switzerland 
2.2 ETHICAL APPROVAL FOR USE OF CRC PATIENT SAMPLES 
Ethical approval for ‘A pilot study of circulating tumour DNA in advanced colorectal cancer’ 
(ref 16/STH/158) was obtained from the Ministry of Health; Health and Disability Ethic 
Committee. Patients were recruited from two study locations within New Zealand, Dunedin 
and Auckland. Informed consent for the use of FFPE tumour block tissue and the collection 
of blood samples from patients who had undergone surgical removal of their primary CRC 
tumour and were receiving chemotherapy treatment was obtained when patients attended 
their oncology departments. 
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2.3 DNA EXTRACTION FROM CRC PATIENT SAMPLES 
2.3.1 FFPE DNA EXTRACTION FROM PRIMARY TUMOUR BLOCKS 
Formalin-fixed paraffin-embedded (FFPE) primary tumour blocks from CRC patients were 
sliced into 5 µm and 10 µm sections using a Leica RM 2125RT Sectioner (Biostrategy, New 
Zealand). These tumour sections were then placed in a Leica HI1210 Water Bath 
(Biostrategy, New Zealand) at 40C for 30 to 60 seconds to allow the sections to soften and 
disperse before they were mounted onto a glass microscope slide (Marienfeld, Germany). The 
slides were then dried in an oven (Contherm Thermotec 2000 Oven, Contherm Scientific Ltd, 
New Zealand) at 55C for 3 hours and stored in a microscope slide box at room temperature 
until required for DNA extraction. 
To distinguish between cancerous tissue and normal tissue in the mounted FFPE tumour 
sections, 5 µm sample slides were stained with Mayer’s Haematoxylin Solution (Sigma 
Aldrich, USA) and Eosin Y Solution (Sigma Aldrich, USA) in a fume hood (Thermoplastic 
Engineering Ltd, New Zealand). Cancerous tissues were carefully scraped off with a sharp 
and sterile blade from 2-3 10 µm slides per FPPE tumour and transferred into a 1.5 mL 
microcentrifuge tube (Eppendorf, USA). DNA from these FFPE tissues was then extracted 
using the QiAmp DNA FFPE Tissue Kit (Qiagen, USA), as per the manufacturer’s protocol. 
However, 30 µL of UltraPure DNAse/RNAse free distilled water (Thermo Fisher Scientific, 
USA) was used for the final elution step of this protocol, in place of the ATE buffer supplied. 
The concentration of extracted FFPE DNA was then quantified using a Qubit 2.0 Fluorometer 
(Thermo Fisher Scientific, USA) and accompanying High Sensitivity dsDNA Kit (Thermo 
Fisher Scientific, USA) as per the manufacturer’s protocol. Samples with FFPE DNA 
concentrations below 10 ng/µL or elution volumes less than 10 µL were excluded from 
further experiments. Approximately 80% of samples in the cohort were extracted by a fellow 
Page | 18  
 
laboratory member in the Cancer Genetics Laboratory (University of Otago, New Zealand) 
and had been used in previous experiments. Samples were stored at -20C prior to use. 
2.3.2 ctDNA EXTRACTION FROM BLOOD SAMPLES 
Ten millilitre (mL) blood samples were drawn from CRC patients by venepuncture into 5X 
Cell-Free DNA Collection Tubes® (Roche, Switzerland) by a registered nurse or 
phlebotomist. Samples were collected immediately prior to chemotherapy treatment then 
brought to the Cancer Genetics Laboratory (Department of Biochemistry, University of 
Otago, Dunedin, New Zealand) and stored upright in a test tube rack at 22C until the 
maximum delay time of 7 days prior to sample processing.  
The blood samples were centrifuged (Eppendorf centrifuge 5810R) at 200 rcf then 1600 rcf 
for 10-minute intervals. The plasma was then siphoned from atop the red blood cells (RBCs) 
via careful pipetting and transferred into 15 mL centrifuge tubes (Greiner Bio-One, Austria). 
Plasma samples were spun again at 1600 rcf to remove cell debris and intact white blood cells 
(WBCs) before being transferred again to 5 mL Eppendorf tubes and stored at -80C prior to 
use. 
Cell-free DNA (cfDNA) was extracted from plasma samples using the QIAmp Circulating 
Nucleic Acid Kit (Qiagen, USA) as per the manufacturer’s protocol for 4 mL of plasma. 
However, 52 µL of UltraPure DNAse/RNAse free distilled water (Thermo Fisher Scientific, 
USA) was used for the final elution step in place of the supplied Buffer AVE. The ctDNA 
samples extracted were then stored at -80C prior to use. 
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2.4 PRE-SEQUENCING AMPLIFICATION OF RNF43 EXONS 
2.4.1 DESIGN OF MULTIPLEX PRIMERS 
PCR primers designed to amplify the coding regions of RNF43 were designed using 
Primer3Plus [56] and NCBI Primer BLAST [57]. Overlapping primers for the large RNF43 
exon 8 (Fig. 3.2) were designed using Primer3Plus following the parameters for multiplex 
PCR primer design. Primers for exons 1-7 and 9 were designed by a member of the Cancer 
Genetics Laboratory, Dr. Robert Day, prior to this project.  
Primers were ordered from Integrated DNA Technologies (IDT), USA and made up to a 
stock concentration of 100 µM with UltraPure™ DNAse/RNAse-Free Distilled Water 
(Thermo Fisher Scientific, USA) upon arrival. These stocks were then diluted to working 
concentrations of 10 µM for further experiments and all primers were stored at -20 C. 
Primer sequences are shown in Table 2.1. 
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Table 2.1 Primer sequences for PCR amplification of the RNF43 gene in CRC patients. 

















































Exon 8 of 9 
RNF43 P1 5’_ATGGTTGAAGTGCATTGCTG_3’ 5’_AGCAGTAGAAGCCCGTGTATG_3’ Exon 1 of 9 




Exons 3 and 
4 of 9 
RNF43 P5 5’_GACCCTTTCCCTCTCTGCTC_3’ 5’_AAAGACCCCACACTGCTCAC_3’ Exon 5 of 9 
RNF43 P6 5’_ATCTGAGCCCCATTCCTCTT_3’ 5’_TCAATCTCCCCAGTCTGGTC_3’ Exon 6 of 9 
RNF43 P7 5’_CCTGGCAATTCCTATGGCTA_3’ 5’_TGCCTACACAGAGGGGAGTC_3’ Exon 7 of 9 
RNF43 P9 5’_TTCCTCCCCGCTCTCTAAAT_3’ 5’_GTCCTTTCCTTTCCCAGGAG_3’ Exon 9 of 9 
1Refer to Figure 3.2 for visual representation of amplicon locations in RNF43 gene. 
 
2.4.2 OPTIMISING MULTIPLEX PCR FOR AMPLIFICATION OF RNF43 EXONS 
Two rounds of PCR experiments were required for pre-sequencing amplification of RNF43 
exons. Forward and reverse (F+R) primer mixes were prepared to 10 µM for each primer pair 
and used as working solutions for the first round of PCR (PCR1). F+R primer mixes were 
added to multiplex PCR primer pools (Fig. 3.2), which were used to make PCR1 master 
mixes with patient FFPE DNA, FastStart Taq DNA Polymerase (Roche, Switzerland), 
FastStart Taq DNA Polymerase PCR buffer (10x conc.) with MgCl2 (Roche, Switzerland), 
PCR Grade Nucleotide Mix (Roche, Switzerland), and varying amounts of UltraPure™ 
DNAse/RNAse-Free Distilled Water (Thermo Fisher Scientific, USA) as shown in Table 2.2. 
PCR1 samples were then run on a C1000 Touch™ Thermal Cycler – Bio-Rad, USA 
according to the protocol in Table 2.3.  
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Table 2.2 PCR1 mastermix example. 
Component Volume per tube (µL) 
10x PCR buffer + Mg2+ [10x conc.] 2.5 
dNTPs [10 µM] 0.5 
Taq DNA Polymerase [5 U/µL] 0.2 
H2O1 16.3 
10 μM F + R mix2 4.5 
DNA [40 ng/µL] 1 
Total 25 
1UltraPure™ DNAse/RNAse-Free Distilled Water – Thermo Fisher Scientific, USA. 
210 µM solution of forward and reverse primers. 
 
Table 2.3 PCR1 protocol. 
Step Temperature (C) Time (seconds) 
1 95 240 
2 95 30 
3 56 30 
4 72 35 
Repeat from step 2 for 29 cycles 
5 72 420 
6 12 ∞ 
PCR1 products were cleaned – removing contaminants and short PCR products – using 
Agencourt AMPure XP beads (Beckman-Coulter, USA) according to the manufacturer’s 
protocol. The bead to sample ratios were optimised based on the size of products (Fig. 2.1), 
which was predicted based on the primer amplicon sizes plus the primer lengths. The clean-
up protocol was optimised by increasing time for DNA binding to and elution from beads 
from 5 minutes to 10 minutes for maximum DNA recovery. Samples were also placed on the 
Agencourt SPRIPlate 96 Super Magnet Plate (Beckman-Coulter, USA) for ~10 minutes to 
allow beads and sample to separate, rather than 2 minutes. 
Page | 22  
 
The DNA concentration in each cleaned sample was quantified using a Qubit 2.0 Fluorometer 
(Thermo Fisher Scientific, USA) and accompanying High Sensitivity dsDNA Kit (Thermo 
Fisher Scientific, USA) as per the manufacturer’s protocol.  
Following clean-up and DNA quantification, PCR1 products were prepared for the second 
round of PCR (PCR2). PCR1 products were diluted to between 1 and 10 ng/µL, pooled for 
each patient, and made up to 15 µL with UltraPure™ DNAse/RNAse-Free Distilled Water 
(Thermo Fisher Scientific, USA) as shown in Supplementary Table 2. Unique combinations 
of Illumina sequencing barcodes were assigned to each patient (Suppl. Table 3) so they could 
be distinguished by the MiSeq System during DNA sequencing and were added to the 15 µL 
samples. A PCR2 master mix was also prepared (Table 2.4) and added to the samples, which 
were then run on a C1000 Touch™ Thermal Cycler – Bio-Rad, USA according to the 
protocol in Table 2.5. 
  
Figure 2.1 Bead to sample clean-up ratios for Agencourt Ampure XP beads (Beckman-
Coulter, USA). Bead to sample ratio (right) corresponds to the peak of each line in the 
graph (left), which indicates the length of PCR products that the ratio is best suited to 
clean. Example of bead-clean up samples is shown in Supplementary Table 1. 
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Table 2.4 PCR2 mastermix example. 
Component Volume per tube (µL) 
10x PCR buffer + Mg2+ [10x conc.] 2.5 
dNTPs [10 µM] 0.5 
Taq DNA Polymerase [5 U/µL] 0.2 
H2O1 16.3 
10 μM F + R mix2 4.5 
DNA [40 ng/µL] 1 
Total 25 
1UltraPure™ DNAse/RNAse-Free Distilled Water – Thermo Fisher Scientific, USA. 
210 µM solution of forward and reverse primers. 
 
Table 2.5 PCR2 protocol. 
Step Temperature (C) Time (seconds) 
1 95 240 
2 95 30 
3 68 30 
4 72 35 
Repeat from step 2 for 15 cycles 
5 72 420 
6 12 ∞ 
PCR2 samples were cleaned using the same optimised Ampure XP bead protocol as for the 
PCR1 products. However, the minimum bead to sample ratio was used (0.9X) for all samples 
as all amplicons were at the maximum clean-up length (~350 bp) due to the Illumina 
sequencing barcodes. DNA concentrations were also quantified after clean-up of PCR2 
products, before samples were prepared for DNA sequencing. 
2.4.3 CONFIRMATION OF PCR PRODUCTS 
Capillary electrophoresis analysis was done on 1 µL of each PCR1 sample using the Agilent 
2100 Bioanalyser (Agilent, USA) with the High Sensitivity DNA analysis kit (Agilent, USA). 
Samples were diluted to between 1-10 µL for multiplex PCR pools and 1 µL for individual 
PCR products. These dilutions were combined into one sample for each patient and run on a 
High Sensitivity DNA Bioanalysis chip (Agilent, USA) according to the manufacturer’s 
protocol. The results of this analysis were visualised in the Agilent 2100 Bioanalyser Expert 
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Software (Agilent, USA) and each PCR product could be non-specifically identified by their 
relative lengths (Fig. 3.3 and Table 3.2). 
2.5 DNA SEQUENCING OF PATIENT SAMPLES 
2.5.1 MULTIPLEX NEXT GENERATION SEQUENCING 
DNA sequencing was performed on the Illumina MiSeq platform (Illumina, USA) for 27 
CRC patients. Unique combinations of Illumina sequencing barcodes were assigned to each 
patient (Suppl. Table 3) so they could be distinguished by the MiSeq System during 
multiplex DNA sequencing. PCR2 samples for all patients were combined into one sample 
for sequencing, with a total concentration of 4 nanomolar (nM). This sample was then 
prepared using a MiSeq V2 Nano 500 bp Kit (Illumina, USA) according to the 
manufacturer’s protocol and run on the Illumina MiSeq platform (Illumina, USA). Sequence 
files in ‘.fastq’ formats were generated for each patient and downloaded from the Illumina 
Basespace Sequence Hub (Illumina, USA) for further computational analysis. 
2.5.2 CONFIRMATION OF RNF43 MUTATIONS VIA SANGER SEQUENCING 
Regions of DNA sequences containing RNF43 mutations were sent to the Genetic Analysis 
Services (University of Otago, Dunedin, New Zealand) for Sanger sequencing. The PCR 
primers required to amplify these regions before sequencing were identified using the 
RNF43-201 Human Transcript in the Ensembl genome browser (release 101) [58]. Samples 
were prepared for PCR according to Table 2.1 and run on the PCR protocol detailed in Table 
2.3. However, PCR for these samples was run for 40 cycles instead of 29. PCR products were 
cleaned using a NucleoSpin® Gel and PCR Clean-Up Kit (Macherey-Nagel, Germany) 
according to the manufacturer’s protocol. However, the clean-up column and Buffer NE were 
incubated at 70C for 5 minutes prior to the final centrifugation step to optimise ethanol 
evaporation and DNA recovery yield. 
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Clean samples were run on a 2.0% Agarose gel using Multi-purpose HyAgarose™ LE 
Agarose (HydraGene, USA), 1X TAE buffer diluted from 10X TAE Buffer stock (Sigma 
Aldrich, USA), gel loading dye (New England Bio-Labs, USA), and DNA Marker 1 (A&A 
Biotechnologies, Poland) according to the manufacturers’ protocols for 20 minutes at 120 
Volts (Suppl. Fig. 1). 
The final samples for sequencing were prepared by diluting the clean PCR product 1 in 10 
then adding 1 µL of diluted PCR product to 1 µL of forward or reverse primer and 3 µL of 
MilliQ® water.  
2.6 BIOINFORMATICS ANALYSES OF RNF43 MUTATIONS 
2.6.1 GALAXY AUSTRALIA ANALYSIS OF DNA SEQUENCING DATA 
DNA sequencing files were downloaded as ‘.fasta’ files from the Illumina BaseSpace 
Sequence Hub and imported into the Galaxy Australia server (https://usegalaxy.org.au/) [59] 
for analysis. A ‘FastQC’ Quality Control analysis [60] was performed on these sequence files 
to check the initial quality of this raw data. The ‘TrimGalore!’ script was then used on its 
default settings to trim the paired-end data and remove adaptor sequences. A second FastQC 
analysis was performed on this trimmed data to ensure that overall sequence quality had been 
improved. Trimmed data was then processed by the ‘fastp’ tool [61], which filtered out low 
quality reads and was set to exclude reads with lengths shorter than 60 base pairs (bp). The 
‘Bowtie2’ alignment tool [62] was used to map the fastp dataset to the Human (hg19) 
reference genome. An ‘mpileup’ was then generated for the alignment using the ‘samtools 
mpileup’ tool [63] – also using the Human (hg19) reference genome – and this mpileup was 
used for variant calling by the ‘VarScan’ tool [64] to identify likely mutations in the 
sequencing data. The parameters for calling these variants are listed in Table 2.6 and vary for 
single nucleotide variations (SNV) and insertion/deletion (indel) mutations.   
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VAF = variant allele frequency. HOM = frequency to call homozygous. 
2.6.2 SEQMONK ANALYSIS OF DNA SEQUENCING DATA 
The ‘Bowtie2’ alignment tool created a bam file for each patient that could be downloaded 
from the Galaxy server and imported to the SeqMonk application (Version 1.47.0; Babraham 
Bioinformatics, UK) for visualisation of DNA sequencing coverage for the RNF43 gene (Fig. 
3.2). The human genome GRCh37 (hg19) was used as a reference and the ‘Ctrl + F’ function 
was used to skip straight to the RNF43 gene. Read position probes were generated for the 
‘currently visible region’ and then quantitated to give coverage depth – ensuring that the 
output would not be expressed as a percentage of all reads. To visualise overlapping 
amplicons in exon 8, probes were then filtered by position using the locations of the amplicon 
in the genome. Using these techniques, amplicons missing from DNA sequencing data could 
be visualised and subsequently added to fill-in experiments. 
2.6.3 VARSOME ANALYSIS OF RNF43 MUTATIONS 
The Human Genomic Variant Search Engine (VARSOME) [65] was used to search for 
mutations in the RNF43 gene identified by VarScan analysis on the Galaxy server. This 
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search engine was used to find the coding impacts, pathogenicity predictions, population 
frequencies, and conservation scores of affected regions for each mutation (Table 3.5). 
2.7 DROPLET DIGITAL PCR OF VIABLE RNF43 MUTATIONS 
2.7.1 DESIGN OF PRIMERS AND PROBES 
Primers and probes for RNF43 mutations were designed using a combination of Primer3plus 
and NCBI Primer BLAST following the guidelines from SantaLucia (1998) [66]. The product 
range was set to 60-100 bp long with the forward and reverse primer sized opted to range 
from 15 to 36 bp and the optimal length set to 20 bp to improve quantification. The melting 
temperature of the primers were set between the range of 50 to 65C, with the optimal 
temperature set to 60C and at least one G or C was added within the 3’ end and – if possible 
– also on the 5’ end.  
The length of the probes was limited to 15-27 bp, with 20 bp being the optimal length to 
prevent cross-reactivity. Probes were designed to have more Cs than Gs and it was ensured 
that a G was not in the 5-prime (5’) end to avoid fluorophore quenching. The melting 
temperature (Tm) was set between 62C and 70C with the optimal temperature being 63C. 
The concentration of divalent cations and dNTPs was set to 3.8 nM and 0.8 nM, respectively, 
for both the primers and probes. The specificity of the forward and reverse primers created in 
Primer3Plus were then checked with the NCBI PrimerBlast software. The primer and probes 
were ordered from Integrated DNA Technologies, USA at a stock concentration of 100 nM 
and diluted to 20 nM to create a working stock. Probes were ordered with the reporter 
fluorophores dyes FAM (mutant) and HEX (wild type), and the double quencher ZEN™ and 
the 3’ Iowa Black FQ to increase detection sensitivity and lower background interference. 
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Table 2.7 Primer and probe sequences for RNF43 mutations in CRC patients. 
Mutations Primer Sequence 
RNF43 
c.1422_1423delTT 
Forward Primer 5’- AGT GAC TCC AGC TCA GG -3’ 
Reverse Primer 5’- TGA TGT CCG TGC AGT TG -3’ 
Wild Type Probe 5’- / 5HEX / CAT GGC TCT / ZEN / TCC 
AGT GAC TC / 3IABkFQ / -3’ 
Mutant Type Probe 5’- / 56-FAM / CAT GGC TCC / ZEN / CAG 
TGA CTC / 3IABkFQ / -3’ 
RNF43 
c.1093G>A 
Forward Primer 5’- ACT ACC ACC TCC CTG CT -3’ 
Reverse Primer 5’- ATG GCA GGA AGG GAC CA -3’ 
Wild Type Probe 5’- / 5HEX / CCG GAG TGC / ZEN / ACT 
GGC TC / 3IABkFQ / -3’ 
Mutant Type Probe 5’- / 56-FAM / TCC CGG AGT / ZEN / ACA 
GTG GCT / 3IABkFQ / -3’ 
2.7.2 OPTIMISING MELTING TEMPERATURE 
ddPCR assays were optimised using the protocol described by Cancer Genetics Laboratory 
member Judy-Ann Cocadiz (2020). Optimal melting temperature was determined using an 
initial gradient ddPCR assay for the ctDNA samples of each patient sample (Table 2.8) 
according to the manufacturer’s protocol. UltraPure DNAse/RNAse Free Distilled Water 
(Thermo Fischer Scientific, USA) was used as the negative control. Human Genomic DNA 
(Roche, Switzerland) diluted to ~30 ng/µL was used as the wild-type healthy control to detect 
false-positive droplets that may be caused by non-specific binding of probes, primer dimer 
formation, or cross-contamination between samples. Once the mastermix was pipetted into 
the wells, the 96-well plate was temporarily sealed and centrifuged using a Select Spin Plate 
Centrifuge (Select BioProducts, USA) to ensure all samples were at the bottom of the wells 
prior to droplet generation.  
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Table 2.8 Gradient ddPCR mastermix example. 
Reagent Volume (µL) 
Supermix for probe (no dUTPs) 11.0 
Forward primer 0.66 
Reverse primer 0.66 
Mutant type probe 0.22 




Droplets were generated from each sample using the QX200™ AutoDG Droplet Digital PCR 
System (Bio-Rad, USA) as per the manufacturer’s protocol. The plate of newly generated 
droplets was then sealed using a PCR Thermal Seal RT2RR™ (Excel Scientific Ltd, USA). 
The C1000 TouchTM Thermal Cycler [Bio-Rad, USA] was then used to amplify droplet 
products following sample preparation according to Table 2.9. This ddPCR required a 
gradient temperature range of between 52C and 62C (Table 2.10). 
Table 2.9 Gradient ddPCR protocol. 
Step Temperature (C) Time (seconds) 
1 95 600 
2 94 30 
3 52-62 60 
Repeat from step 2 for 39 cycles 
4 98 600 
5 12 ∞ 
 
Table 2.10 Temperature gradient for the 96-well plate. 
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Following amplification, target wild type and mutant type droplet concentrations were 
quantified using the QX200™ Droplet Reader (Bio-Rad, USA) that passed the droplets 
through a two-colour detector and classified them as either positive or negative depending on 
their fluorescence amplitude [48]. The samples were evaluated through the Rare Event 
Detection (RED) experiment and the fluorescent probes were measured using FAM for the 
mutant type and HEX for the wild type target. 
The results of these quantifications were then exported into the QuantaSoft Analysis Pro 
Software (Bio-Rad, USA) for further data analysis. A threshold was set manually to 
distinguish between wild type or mutant type, background, and false-positive or false-
negative droplets. The temperature at which the assay was observed to have the best 
separation of wild or mutant type to background droplets was considered the optimal melting 
temperature (Tm). 
2.7.3 DDPCR ASSAY TO DETECT RNF43 MUTATIONS ON ctDNA 
The optimised Tm was used for assays (Table 2.11) on ctDNA extracted from a series of 
blood collection cycles for patient M032. Following amplification, the mutant droplet 
concentration for each cycle was quantified using the QX200™ Droplet Reader (BioRad, 
USA) and evaluated through the Rare Event Detection (RED) experiment. The fluorescent 
probes were measured using FAM for the mutant type and HEX for the wild type target. A 
threshold was set manually in the QuantaSoft Analysis Pro Software (Bio-Rad, USA) to 
distinguish between wild type or mutant type, background, and false-positive or false-
negative droplets. Concentration data in copies per µL reaction were exported to Microsoft 
Excel for further analysis. 
  
Page | 31  
 
Table 2.11 ddPCR mastermix example. 
Component Probe Volume (µL) 
Mastermix  11.0 
Assay 1 
Forward primer 0.66 
Reverse primer 0.66 
Mutant type probe 0.22 
Wild type probe 0.22 
Assay 2 
Forward primer 0.66 
Reverse primer 0.66 
Mutant type probe 0.22 
Wild type probe 0.22 
Water  1.48 
Sample  6.00 
Total  22.0 
All primers and probes used at  
2.7.4 DATA ANALYSIS 
Concentration data for the M032 ddPCR assay was exported to Microsoft Excel to calculate 
the final mutant droplet concentration (mutation copies per mL plasma ± SEM) for the 
RNF43 c.1422_1423delTT mutation in M032. This standard error mean (SEM) was 
calculated from 4 repeats for each ctDNA collection cycle (Suppl. Table 4). A scatter graph 
was then generated to visualise changes in droplet concentration of the RNF43 mutation in 
comparison to mutations in BRAF and EGFR (Fig. 3.7), which were assayed previously for 
M032 by fellow members of the Cancer Genetics Laboratory, Donghui Zhou and Judy-Ann 
Muñoz Cocadiz (Department of Biochemistry, University of Otago, Dunedin, New Zealand).  
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3 RESULTS 
Tīkarohia te marama.6 
The whakataukī for this section reflects the rigorous process required in research to draw key 
pieces of information from huge data sets, and the importance of researchers being able to 
structure these results into a narrative. 
The aims of my research were to develop a method for rapidly identifying mutations in the 
RNF43 gene and to explore the likely utility of RNF43 mutations as CRC ctDNA markers. 
This novel sequencing protocol was developed to yield high quality DNA sequences for 
RNF43 in a cohort of 30 NZ CRC patients, on which mutational analyses of the gene were 
then performed.  
3.1 METHOD DEVELOPMENT 
Development of a novel sequencing protocol that could accurately identify mutations in the 
RNF43 gene was a key objective and therefore constitutes a majority of the results for this 
project. This method development required three key steps. Firstly, optimisation of pre-
sequencing PCR was required to ensure only coding regions of the gene were amplified. 
Secondly, regions of the gene that were unsuccessfully amplified or sequenced had to be 
identified so the gaps could be filled before mutation analysis. Lastly, errors in DNA 
sequencing had to be identified to ensure that only genuine RNF43 mutations were further 
characterised.  
At the outset of this project, an amplicon-based DNA sequencing protocol for the RNF43 
gene was not yet established in the Cancer Genetics Laboratory nor described in the 
 
6 Seek out that which is most important. 
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literature. Therefore, the first aim of this project was to develop a protocol that optimised 




Figure 3.1 Summary of experimental methods used to develop a novel sequencing 
protocol for RNF43, resulting in high quality DNA sequence data for mutation analysis. 
First round PCR amplified target regions of interest. Clean-up used a standard Ampure XP 
bead protocol and consequent DNA concentration from each sample was measured using 
Qubit fluorometric quantitation (Thermofisher). Bioanalysis used the Agilent 2100 
Bioanalyser system and High Sensitivity DNA kits and reagents. Second round PCR 
attached oligonucleotide sequences of Illumina adapters for preparation of MiSeq DNA 
sequencing library. DNA sequence quality was checked in Galaxy (Australia) via Bowtie2 
mapping tool. Amplicon presence in sequence was checked in SeqMonk application via 
sequence mapping to human reference genome hg19. 
 
FFPE = formalin-fixed paraffin embedded. CRC = colorectal cancer. [DNA] = 
concentration of DNA. PCR = polymerase chain reaction. 
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3.1.1 OPTIMISATION OF PRE-SEQUENCING PCR EXPERIMENTS 
This sequencing protocol required two separate PCR steps: the first step (PCR1) used custom 
designed primers to specifically amplify the coding regions of RNF43 and the second step 
(PCR2) was used to add Illumina sequencing barcodes to the PCR1 amplicons, which would 
allow for unique identification of DNA sequences for each patient on the Illumina MiSeq 
sequencing platform. Only coding-region sequences of RNF43 were required for analysis of 
mutations as the consequences of non-coding mutations are difficult to ascertain [49]. The 
structure of the RNF43 gene contains large introns and 9 exons – one of which is relatively 
large (~1.3 kb) – so a total of 28 PCR1 primers were designed to target each exon, with 14 of 
these primers overlapping to cover the large exon (Fig. 3.2).  
 
All primers were initially designed using Primer3plus and Primer BLAST with the following 
criteria: similar annealing temperatures (~60C) for efficiency in multiplex reactions, 
similarly low GC content (50-60%), and no non-specific DNA targets. 
Primers were then sorted in multiplex PCR pools, which allow for more time efficiency than 
performing 14 uniplex reactions for each patient in the cohort. Primers were initially sorted 
into pools based on their amplicon lengths – pools (a) and (c) produced amplicons ~200 bp 
long and pools (b) and (d) produced amplicons ~400 bp long – and the exons they covered – 
Figure 3.2 Visual representation of RNF43 exon coverage by custom designed PCR 
primers. Colours indicate multiplex PCR pools: (a) purple, (b) green, (c) yellow, (d) 
orange. Amplicons in red indicate those run in uniplex. Pools (a) and (c) produced 
amplicons ~200 bp long and pools (b) and (d) produced amplicons ~400 bp long. 
 
‘CP’ indicates amplicons for exon 8. ‘P’ indicates amplicons for the other RNF43 exons.   
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pools (a) and (b) covered exon 8 and pools (c) and (d) covered the other exons of the RNF43 
gene. Amplicons in each PCR pool were required to be similar sizes to avoid preferential 
amplification of shorter amplicons. Primers with overlapping amplicons were also required to 
be kept separate to avoid creation of unintended amplicons between forward and reverse 
primers from separate pairs. Following this initial sorting, the online ‘multiple primer 
analysis’ tool (Thermofisher, USA) was then used to reorganise primers in each pool if they 
were predicted to form self- or cross-primer dimers – undesirable by-products that lower 
efficiencies of multiplex reactions. Some amplicons, coloured in red (Fig. 3.2), were 
frequently missing in subsequent experiments and were run in uniplex to ensure total 
coverage of the target gene where possible. 
Following each PCR step, samples were cleaned using Ampure XP beads (Beckman-Coulter) 
and bead to sample volume ratios were optimised according to the minimum amplicon length 
in the pool to ensure the smallest fragments were not lost during the clean-up process. For 
PCR1 amplicons, average minimum lengths were ~200 bp and ~400 bp – depending on the 
multiplex pool – and for PCR2 amplicons, which were entirely pooled, the overall average 
minimum length was ~350 bp. Concentrations of DNA for each sample after clean-up was 
quantified using a 2.0 Qubit fluorometer and patients that had low values (<10 ng/µL) were 
excluded from further experiments as MiSeq sequencing requires a minimum concentration 
of 4 nM of DNA to be successful. 
Following clean-up and DNA quantification, samples were run on a Bioanalyser (Agilent, 
USA) to confirm that all RNF43 target regions were present for every patient. The 
Bioanalyser is able to precisely call highly specific lengths (bp) of each amplicon. A normal 
trace is shown in Figure 3.3, where all amplicons can be identified – though some amplicons 
are similar sizes and occur in the same peak. Primer pairs that were frequently missing in 
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Bioanalyser traces were run separately in uniplex PCR to ensure total coverage of the target 
gene where possible – these primer pairs are indicated in red in Figure 3.2. Following DNA 
sequencing on the Illumina MiSeq sequencing platform, DNA sequences were checked in the 
SeqMonk application that allowed visualisation of total gene coverage (Fig. 3.4). For regions 
of the gene missing from this sequencing data, ‘fill-in’ experiments were conducted whereby 
primer pairs covering missing regions were run in uniplex to ensure optimal PCR conditions. 
Sequencing data for both the original sequences (with gaps) and fill-in sequences were then 
combined using the online bioinformatics platform, Galaxy (Australia). 
A total of four rounds of optimisation experiments were required to establish the final method 
sequence for obtaining high quality DNA sequencing data in a time and cost-efficient manner 
(Table 3.1).    
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Table 3.1 Summary of the five rounds of experiments used to optimise pre-sequencing 
targeted region amplification of RNF43. 
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1‘Drop-out’ amplicons were those that were consistently missing from Bioanalysis traces. 
2Bead clean-up ratios were optimised again to account for the additional lengths of PCR1 primers and PCR2 
sequencing barcodes. 
3Supplementary Figure 2. 
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The first round gave a general idea of PCR primer efficiency in multiplex reactions and how 
to best identify missing amplicons pre-sequencing. From this first round of sequencing, it was 
also determined that small sample sizes resulted in over-saturation of sequencing flow-cells, 
which results in poor DNA sequence quality.  
The second round used larger sequencing cohorts and primers that frequently ‘dropped-out’ 
of multiplex PCR were identified and run individually. Additional time saving steps were 
also optimised and clean-up procedures were improved. 
In both the third and fourth rounds, gaps in DNA sequences were identified post-sequencing 
using the SeqMonk application, which allowed for region-specific identification of amplicons 
that ‘dropped out’ of multiplex PCR. These gaps could be filled in retrospectively in the next 
round of experiments, using the same Illumina sequencing barcode identifiers for each patient 
to allow for better combination of sequencing results. 
The fifth round was purely to fill-in gaps identified in sequences to achieve high total 
coverage of the RNF43 gene (95% average percentage aligned reads) for 24 patients in the 
cohort. This protocol optimised time and cost efficiencies and was able to identify two likely 
pathogenic RNF43 mutations and ddPCR assays were designed to determine the utility of 
these mutations for surveying CRC in comparison to current ctDNA biomarkers.  
3.1.2 IDENTIFYING GAPS IN RNF43 DNA SEQUENCE 
Amplicons that frequently ‘dropped out’ of multiplex PCR or were absent from DNA 
sequencing data were identified between PCR experiments via amplicon length determination 
(Fig. 3.3, Table 3.2) and after DNA sequencing using computational analyses (Fig. 3.4).  
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Table 3.2 Bioanalysis peaks for patient M022 can be assigned to PCR1 amplicons based on 
their relative lengths. 
Amplicon Predicted length1 (bp) Bioanalysis length2 (bp) 
P5 194 197 
P9 199 205 
NA NA 223 
P7 237 241 
NA NA 265 
P6 276 280 
P2/CP6 286/316 290 
CP7 300 314 
CP5 344 343 
CP1/CP4 378/380 399 
P1/CP2/CP3 423/422/454 411 
1Total predicted length of amplicons plus their PCR1 primers. 
2Total actual length of amplicons as determined by Bioanalysis. 
NA indicates an unassigned peak present on the Bioanalysis trace. 
  
Figure 3.3 Bioanalysis trace of patient M022 PCR1 products can identify relative 
successes of PCR amplification of RNF43 target regions. Peak heights correspond to the 
average concentration of amplicons present at the lengths indicated above them. Upper 
(purple) and lower (green) markers indicate the size range of the Bioanalysis trace. An 
Agilent 2100 Bioanalyser (Agilent, USA) was used for this experiment, courtesy of the 
Otago Genomics Facility (Department of Biochemistry, University of Otago, Dunedin, 
New Zealand). The molecular ladder for this trace was normal (Suppl. Fig. 3). 
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Multiplex PCR1 pools were combined for each patient then run on an Agilent 2100 
Bioanalyser (Agilent, USA). This analysis allowed non-specific identification of amplicons 
based on their predicted lengths. Amplicons with similar predicted lengths such as CP1 and 
CP4 (378 bp and 380 bp, respectively) were unable to be distinguished from one another 
using this method, so it was presumed for most samples that peaks in this range identified 
both fragments. Additional experiments were carried out in Round 4 of PCR1 optimisation 
where amplicons of similar lengths were run separately for a patient to confirm this 
possibility. Further experiments were also carried out that identified the source of the 
unassigned peak at ~261 bp present in all patient samples were the results of PCR products 
created by unintended interactions between primer pairs P2 and P34. Additionally, extra 
experiments determined that amplicons CP6 and CP3 were running at unexpectedly short 
lengths of ~316 bp and ~289, respectively. 
Gaps in DNA sequences were more specifically identified post-sequencing using the 
SeqMonk application to visualise data (Fig 3.4).  
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Figure 3.4 shows the alignment for four patients, who had an average of 98% of their 
sequenced reads aligned to the reference genome hg19. As indicated by the red oval, patient 
M004 was missing reads aligned to exon 1. These were then targeted specifically in the final 
round of fill-in experiments to ensure maximum coverage of the RNF43 gene was obtained 
for all patients. This ensured that mutation analysis was representative of the entire gene. 
Regions of low coverage in DNA sequences were also identified by SeqMonk quantification, 
as can be seen for the low number of reads covering exons 3 and 4 in patient M004. These 
regions were also sequenced again during the ‘fill-in’ experiments. 
Figure 3.4 shows alignment of sequencing data from the SeqMonk application used to 
specifically determine ‘drop-out’ amplicons from DNA sequence data. RNF43 exons are 
shown in the CDS track. The position in the reference genome (hg19) is given by the 
numbers at the bottom of the screen. Each blue rectangle in the window below the CDS 
track indicates a read mapped to these positions in the RNF43 gene (RNF43-201 Human 
transcript). Alignment was performed by Bowtie2 mapping tool in Galaxy (Australia) and 
files were imported to SeqMonk in ‘.bam’ format. Exon 1 is the far-right exon in the 
antisens orientation of the gene. Red oval indicates missing reads. 
 
CDS = coding sequence. 
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3.2 DNA SEQUENCING 
Primary tumour samples from CRC patients were sequenced using the Illumina MiSeq 
platform to generate DNA sequence data that could be analysed for potential mutations in 
RNF43. Six probable mutations were identified by computational analysis and four of these 
were verified by Sanger dideoxy sequencing – a more rigorous form of DNA sequencing – to 
confirm they were not sequencing errors. 
3.2.2 CLINICAL COHORT DESCRIPTION 
The waerea at the beginning of this thesis is considered particularly important to protect the 
patients whose samples were used for this study, the researchers who used these samples, and 
the knowledge obtained from these samples. This study was not specific to Māori, however, 
the waerea offers protection to all patients regardless of any personal affiliations such as 
ethnicity, religion, or otherwise. Donor details were anonymised to protect both their privacy 
and the integrity of the study. However, certain aspects of clinical information were 
considered important for the analysis of CRC in this cohort. This information is summarised 
in Table 3.3.  
The status of APC mutations in the patient cohort was important to note as they are likely to 
be mutually exclusive to pathogenic RNF43 mutations due to the similar roles these genes 
play in the Wnt signalling pathway. Patients who were found to have RNF43 mutations 
classified as ‘pathogenic’ (red), ‘uncertain significance’ (yellow), or ‘likely benign’ (green) 
in the VARSOME database are highlighted. 
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Table 3.3 Clinical information for NZ colorectal cancer cohort.  
Sample 
Age Gender Clinical stage Primary tumour location Metastasis APC2 
M003 65 F 4 sigmoid colon lung N 
M004 76 F 3 caecum no N 
M0051 76 F 4 sigmoid colon liver Y 
M006 73 M 3 rectum no Y 
M0071 67 M 4 sigmoid colon liver, lung, peritoneum N 
M0101 64 F 4 caecum liver, peritoneum N 
M011 73 M 4 caecum liver Y 
M013 60 F 3 ascending colon no N 
M014 56 F 4 rectum lung Y 
M020 56 M 3 rectum no N 
M022 70 M 3 sigmoid colon no Y 
M024 45 M 3 rectum no Y 
M025 61 M 3 splenic flexure, rectum liver, lymph nodes, 
peritoneum, spleen 
Y 
M027 72 F 4 splenic flexure liver N 
M028 60 F 2 transverse colon no N 
M031 50 M 3 appendix no Y 
M032 56 M 4 descending colon lung N 
M035 70 F 3 sigmoid colon no Y 
M036 75 F 3 rectum no N 
M0453 NA NA NA NA NA Y 
M047 76 M 4 sigmoid colon liver Y 
M049 65 F 3 rectum no Y 
M051 77 F 3 ascending colon no Y 
M052 71 M 4 ascending colon lung Y 
M0531 78 F 4 sigmoid colon liver, lymph nodes N 
M054 57 F 3 sigmoid colon liver N 
M055 52 F 4 sigmoid colon liver Y 
M056 56 M 3 rectum lymph nodes Y 
M0571 37 F 4 descending colon liver Y 
M058 71 F 4 hepatic flexure liver, lymph nodes N 
M059 67 F 3 rectum no Y 
1Excluded from DNA sequence analysis due to low sample concentration or volume. 
2Does the sample contain a mutation in the APC gene? Y/N = Yes/No. 
Highlighted rows indicate ‘likely benign’ (green), ‘uncertain significance’ (yellow), and ‘pathogenic’ (red) RNF43 mutations. 
NA indicates missing data. 
3Clinical information for this patient is missing, however, their sample was used in the final sequencing analyses. 
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3.2.1 IDENTIFICATION OF RNF43 MUTATIONS 
A total of 27 patients from the NZ CRC cohort were sequenced using the Illumina MiSeq 
platform. Of these, only 24 generated high-quality DNA sequencing data that could be used 
for analysis of genetic mutations. Excessive sequencing errors were detected in three patients, 
which was probably due to them being pooled in a small sequencing cohort, resulting in 
oversaturation of the sequencing flow-cell.  
A total of 77 RNF43 variants were identified in the 24 tumours using the VarScan software 
on the Galaxy (Australia) server. Of these variants, 47 were also detected in the healthy 
control (genomic DNA from Roche) so were clearly RNF43 germline polymorphisms. A 
further three RNF43 mutations were also excluded as likely experimental errors caused by 
contamination of workspaces with PCR products from previous samples. After filtering out 
the RNF43 mutations that were unlikely to be strong ctDNA biomarkers, a total of six 
variants were identified for use in further experiments. A summary of the criteria used to 
determine which RNF43 variants were viable for further analysis is shown in Figure 3.5. 





Figure 3.5 Summary of filter criteria for identifying viable RNF43 mutations for ctDNA 
surveillance of CRC. All mutations are listed in Supplementary Table 5 and highlighted 
based on the reasoning for their exclusion. ‘Likely experimental errors’ describes 
contamination of workspaces with PCR products from previous samples. 
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3.2.3 ANALYSIS OF RNF43 MUTATIONS 
Following the exclusion criteria of unlikely RNF43 mutations, a total of six patients were 
identified as having probable RNF43 mutations that would serve as informative ctDNA 
biomarkers for CRC. These mutations are summarised in Table 3.4.   
Table 3.4 Probable RNF43 mutations detected by VarScan software tool, Galaxy (Australia) 






Type REF ALT 
Mutant 
Frequency (%) 
M003 56432373 58355012 Intronic G A 98.63 
M022 56436044 58358683 Missense C T 48.22 
M032 56435713 58358352 
Point-
nonsense 
GAA G 78.36 
M004 56435160 58357799 
Point-
nonsense 
AC A 74.45 
M013 56435160 58357799 
Point-
nonsense 
AC A 42.71 
M047 56432355 58354994 Intronic TA T 11.32 
Most of these six RNF43 mutations were detected at high frequencies in CRC tumour 
samples, indicating most tumour clones contain these mutations. Mutation allele frequencies 
above 50% in patients M032 and M004 were consistent with the second allele being lost by a 
deletion event. The intronic mutation in M003 is more likely to be a homozygous 
polymorphism. 
The allele frequencies of the exonic RNF43 mutations indicated that they had occurred early 
in tumour development and may be founder mutations, which are not usually lost to eventual 
tumour evolution. These are the ideal candidates for ctDNA biomarkers as they will 
accurately represent most primary tumour clones. 
The two intronic RNF43 mutations identified were not verified via Sanger dideoxy 
sequencing. The pathogenicity of intronic mutations are difficult to predict unless they form 
part of the consensus splice site sequence, therefore, they were unlikely to be good ctDNA 
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biomarkers. A search of the VARSOME database showed these mutations were located 7 bp 
and 29 bp downstream of splicing sites, so functional impact was unlikely. 
All probable RNF43 mutations were searched in the VARSOME database (Table 3.5). 
Table 3.5 Summary of data from VARSOME search for each probable RNF43 mutation. 

























NA 5.1799 1.74 
1 The Human Genome Variation Society description of DNA sequence variation. 
2 Genomic Evolutionary Rate Profiling is a conservation score ranging from -12.3 to 6.17, with 6.17 
being the most conserved. NR = neutral rate. RS = Rejected substitutions (GERP’s typical score). 
Highlighted row indicates the RNF43 mutation that is the most viable ctDNA marker. 
This VARSOME search found information on all the probable RNF43 mutations, such as 
their effects on amino acid sequences, their current classification according to the American 
College of Medical Genetics and Genomics (ACMG) [67], population frequency, and 
conservation scores for the regions they affect. Population frequencies – that could be found 
– were very rare, clearly indicating these mutations are somatic.  
Two identical pathogenic mutations (c.1976delG) were detected in two patients, which is 
highly unlikely in unrelated persons. Sanger sequencing of this region (Fig. 3.6) showed it 
had long G and C monomeric tracts, so was likely a mutation ‘hotspot’ as it would promote 
DNA polymerase slippage during transcription.  
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The two predicted pathogenic RNF43 mutations resulted in early termination of amino acid 
sequences that truncated the resulting protein. It is important to note that the patients with 
these pathogenic mutations did not contain APC mutations (Table 3.3), so RNF43 mutations 
were likely CRC founders in these patients. Comparatively, the patient with the ‘likely 
benign’ RNF43 mutation did have an APC mutation.  
3.2.4 VERIFICATION OF RNF43 MUTATIONS 
The four exonic RNF43 mutations were verified by Sanger dideoxy sequencing prior to 






























Figure 3.6 Sanger sequencing results for CRC patients with RNF43 mutations. (A) 
RNF43 c.1422_1423delTT mutation; (B) and (C) RNF43 c.1976delG mutation; (D) 
RNF43 c.1093G>A mutation. Patient identifiers for each trace are listed on the right. 
 
Full sequencing service provided by the University of Otago Genetic Analysis Services. 
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This sequencing method has greater accuracy than the Illumina MiSeq method and allows 
visualisation of single nucleotide deletions and substitutions. The traces in Figure 3.6 show 
high peaks for each base call, indicating a lack of contamination and confident nucleotide 
base calls upstream of deletion mutations. Directly downstream of the frameshift mutations 
the DNA sequence is messy due to the lack of alignment of the two alleles. Interestingly, in 
patient M022, the peak height for the mutant and wild-type bases at the position of the single 
nucleotide variant (SNV) mutation is consistent with the mutant frequency (~48%) 
determined by DNA sequencing data from the Illumina MiSeq sequence data. 
3.3 DDPCR ASSAY DESIGN FOR RNF43 MUTATIONS 
Following verification of RNF43 mutations, we attempted to design ddPCR primers and 
probes for each mutation. ddPCR assays were designed for one pathogenic RNF43 mutation 
(c.1422_1423delTT) and one benign (c.1093G>A). However, ddPCR assays could not be 
designed for the RNF43 mutations in the GC rich ‘hotspot’ as this GC repetitive region could 
not be specifically targeted with primers or probes. The pathogenic RNF43 mutation was 
considered the better ctDNA biomarker as it was likely to be a founder mutation for CRC in 
this patient. This prediction is supported by the lack of an APC mutation in this patient. As 
noted earlier, APC mutations are mutually exclusive to RNF43 mutations. Comparatively, the 
patient with a benign RNF43 mutation had an APC mutation, so the benign RNF43 mutation 
was likely a passenger mutation that occurred downstream of the initial driver mutations in a 
subsequent clone. Due to time constraints, only the pathogenic RNF43 mutation was used for 
serial analyses (Fig 3.7).  
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The RNF43 c.1422_1423delTT mutation was identified in the tumour of CRC patient M032 
who underwent 18 months of treatment for metastatic disease. Plasma samples were taken at 
2-4 weekly intervals during this period. These samples had previously been analysed with 
two other ctDNA markers in the EGFR and BRAF genes. Sufficient remaining plasma was 
available for a subset of timepoints to allow for characterisation of the ddPCR assay against 
the c.1422_1423delTT RNF43 mutation. 
Figure 3.7 Serial analysis of three ctDNA markers (RNF43, BRAF, and EGFR mutations) 
can detect discrete changes in tumour burden for CRC patient M032. Separate ddPCR 
assays were used for each ctDNA marker (note log scale). Errors bars show the standard 
mean error (SEM), calculated using four replicates for each time point (Suppl. Fig. 4). 
Vertical dashed lines with triangles indicate clinically determined progressive disease 
status. Different coloured block arrows indicate different chemotherapy treatments. 
FOLFOXIRI: folinic acid, fluorouracil (5FU), oxaliplatin, and irinotecan. FOLFIRI: 
folinic acid, fluorouracil (5FU), and irinotecan. Some samples fall below the y-axis due to 
the log scale, on which 0 mutation copies/mL plasma is impossible to plot so are plotted at 
0.0001. 
 
BRAF and EGFR serial analyses were conducted by Donghui Zou in the Cancer Genetics 
Laboratory, University of Otago, Dunedin, New Zealand. 
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As shown in Figure 3.7, the RNF43 mutation (c.1422_1423delTT) shows higher levels of 
ctDNA than the EGFR and BRAF markers at each point where there was sufficient plasma 
for the analysis of all three markers. This higher apparent tumour burden is likely to indicate 
the presence of a previously undetected clonal population, reflecting the founder mutation 
status of this RNF43 variant. This RNF43 mutation closely follows disease status in this 
patient, where relative increases and decreases of mutation copies (per mL plasma) reflect 
increases and decreases of tumour burden following treatment and disease progression. 
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4 DISCUSSION 
Ko te pae tata, whakamaua, kia tina, ko te pae tawhiti, whāia, kia tata.7 
This whakataukī embodies the nature of cancer research. Cancer research is a constant pursuit 
towards a solution. However, like the horizon, it is a pursuit we will come ever closer to 
without quite reaching it. There will always be more questions to be asked and more solutions 
to be found. This thesis, though it found potential improvements for a cancer surveillance 
technology, also raised yet more questions that will spur further research. As is the nature of 
research. So, though this thesis ends here, the pursuit is infinite. 
4.1 DEVELOPMENT OF A NOVEL SEQUENCING PROTOCOL 
The primary aim of this project was to develop a novel sequencing protocol for a poorly 
characterised gene that was suspected to play a pathogenic role in CRC development. The 
final optimised approach was designed with time- and cost-efficiencies in mind, whilst 
maximising total genome coverage for every patient. This required the use of multiplex 
reactions where possible, and a series of pre-sequencing troubleshooting steps. This final 
protocol may provide a useful guideline for sequencing other less studied genes. 
4.2 RNF43 MUTATIONS 
4.2.1 SEQUENCING RESULTS 
In this cohort, we have identified only somatic RNF43 mutations. The patients had no 
recorded inherited cancers in their families. This leads to the conclusion that no RNF43 
variants detected in this study were likely to be germline,  
 
7 Secure the horizons that are close to hand and pursue the more distant horizons so that they may become close. 
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As part of routine gene testing panels, patients were tested for mutations in mismatch repair 
(MMR) genes that frequently lead to an increase in somatic mutations due to cells being 
unable to repair sequencing errors in DNA. Mutations in MMR genes would therefore likely 
accelerate RNF43 mutations, especially those located in ‘hotspots’ such as the c.1976delG 
mutation. Similarly, mutations in BRAF are likely to accelerate mutations in RNF43, which is 
a known driver of CRC and mutations in BRAF are associated with methylation of MMR 
genes, which in turn could lead to RNF43 mutations. 
The non-pathogenic RNF43 mutations detected were likely passenger mutations. They will 
have lower reliability as ctDNA markers but for cancers where founder mutations are 
unknown, use of passenger mutations as ctDNA biomarkers can be useful.  
4.2.2 DRIVER GENE STATUS 
RNF43 mutations detected in this study were determined to be driver genes based on the 
importance of RNF43 to cancer initiation and their mutual exclusivity with APC mutations. 
Further analyses could also be done that utilise large cohorts and determine driver status 
based on mutation frequency (i.e. the more mutations present in RNF43, the more likely it is 
a driver gene). Alternatively, Vogelstein et al. (2013) [12] developed a ratiometric method of 
identifying mut-driver genes – genes that contain a sufficient number or type of driver gene 
mutations to unambiguously distinguish them from other genes. They identified these through 
their pattern of mutation rather than their mutation frequency and specifically found that 
tumour suppressor genes, such as RNF43 are mutated through protein-truncating alterations. 
4.2.3 FUNCTIONAL AND STRUCTURAL EFFECTS 
The RNF43 mutations in this study that were predicted to be pathogenic were both deletions 
that resulted in an early termination codon. These mutations caused truncation of the RNF43 
protein, which presumably resulted in loss-of-function. However, structural studies should be 
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conducted to determine the effects of this RNF43 variant. Studies by Tsukiyama et al. (2015) 
[68] have indicated that the N- and C-termini of RNF43 are likely to play regulatory roles in 
different parts of the Wnt signalling pathways, so truncation of one over the other may have 
opposite effects. RNF43 was the target of this project as its founder role in CRC development 
is not well characterised. This project determined that from a genetic point of view, it is likely 
a founder gene. However, structural analyses of individual RNF43 mutations, particularly 
deletion mutations, will be helpful for further characterisation of the consequences of these 
mutations on Wnt signalling pathways as a whole. Effects of these RNF43 mutations can be 
further verified by nuclear beta-catenin staining, which verifies whether the Wnt pathway has 
been activated or not [49]. 
4.3 FUTURE WORK 
Circulating tumour DNA analyses have huge potential to improve current methods of 
surveillance for CRC. 
4.3.1 NEXT GENERATION SEQUENCING 
The hotspot mutations detected in RNF43 (c.1976delG) was not able to be assayed in ddPCR. 
However, they may still make good ctDNA markers for RNF43 using methods other than 
ddPCR. Advances in next generation sequencing (NGS) custom targeted gene panels may 
offer the ability to sequence the entire RNF43 gene for detection of ctDNA. In the Cancer 
Genetics Laboratory (University of Otago, Dunedin, New Zealand), Duncan Finlayson is 
currently testing the efficiency of a QiASeq Targeted DNA Panel (Qiagen, USA) in the 
detection of ctDNA from CRC plasma samples. RNF43 is present on this custom designed 
panel and to date, all regions of the RNF43 gene are covered at a minimum average of 1000-
fold (unpublished). This increases the utility of RNF43 mutations as biomarkers for CRC 
surveillance, as previously unassayable mutations could be sequenced using NGS panels.  
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4.3.3 IMPROVING EARLY DETECTION OF COLORECTAL CANCER 
New Zealand has the second highest rates of colorectal cancer in the world. These rates are 
only expected to increase despite improvements in early-screening programmes. 
4.3.4 IMPROVING ACCESS TO CANCER CARE FOR RURAL MĀORI 
COMMUNITIES 
As mentioned earlier, rural Māori cancer patients in New Zealand suffer health inequities that 
restrict access to cancer care. These barriers are primarily due to geographical, 
socioeconomic, and cultural factors that could be overcome by implementation of more 
innovative clinical procedures for cancer management during and after primary treatment.  
Rural Māori communities differ to urban communities as their cancer care is more frequently 
restricted by long travel distances and dispersed healthcare providers. Many in these 
communities forego seeking care due to added restrictions of peak seasonal farm work that 
makes taking time off for treatments or check-ups impossible for such inflexible schedules. 
For rural Māori living with cancer, the increasing specialisation of medicine and associated 
technologies further restricts access to routine check-ups for disease management to regional 
or national healthcare centres. However, these advancing technologies may also have the 
potential to close the deprivation gap between rural and urban communities.  
Circulating tumour DNA (ctDNA) analyses are a promising cancer surveillance tool for these 
communities – as opposed to current methods (Table 1.1) – as they are more accessible, less 
invasive, and can be delivered by Kaupapa Māori or rural health practitioners. De-
specialisation of cancer care reduces travel time, costs, and transport requirements for check-
ups and allows quicker appointments and increased flexibility of healthcare services. 
Therefore, for healthcare interventions to be successful at overcoming the disparities and 
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inequities faced by rural Māori in New Zealand, they must be able to effectively engage with, 
consult, and empower Māori in all aspects.  
It should be noted that ctDNA surveillance has the potential to improve access to cancer care 
for many communities that currently face inequities, and that rural Māori communities are 
only some of the many that may benefit from routine clinical use. 
4.4 SUMMARY 
The aims of this project were to develop a novel sequencing protocol for RNF43, determine 
the frequency of RNF43 mutations in the NZ CRC cohort, and examine the utility of these 
mutations as ctDNA biomarkers for CRC surveillance. This study found that RNF43 
mutations are likely founder mutations for ~13% of CRCs in this cohort, they are mutually 
exclusive to APC mutations, and they can be used to accurately follow tumour burden in 
CRC patients. 
This supports our hypothesis that RNF43 would be a valuable addition to ctDNA gene 
targeting panels for routine ctDNA surveillance of CRC. This improvement to future panels 
will be able to increase the coverage of panels and the proportion of patients for whom the 
panels will be an accurate reflection of disease burden.  
ctDNA analyses have the potential to improve access to cancer care. These methods are more 
accurate and reliable than current surveillance methods, as well as being more cost- and time- 
effective, and accessible. 
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5 APPENDICES 
Supplementary Table 1 Example of bead clean-up ratios for PCR1. 
Pool/amplicon 
Minimum 







(a) 300 0.9 22.5 202.5 
(b) 378 0.7 17.5 157.5 
(c) 194 1.8 45 405 
(d) 286 0.9 22.5 202.5 
(e) 422 0.7 17.5 17.5 
(f) 286 0.9 22.5 22.5 
CP1 378 0.7 17.5 17.5 
CP2 422 0.7 17.5 157.5 
CP3 454 0.7 17.5 157.5 
CP4 380 0.7 17.5 17.5 
CP6 316 0.9 22.5 225 
P1 423 0.7 17.5 17.5 
1Bead/sample ratio determined from graph in Figure 2.1. 
Beads added to entire PCR1 sample (25 µL). 







Water (µL) Sample (µL) Sample (µL) 
Pool (a) 19.6 2 17.6 2 1.0 
Pool (b) 1.03 4 NA NA 3.9 
Pool (c) 26 4 11.0 2 1.0 
Pool (d) 7.21 5 0.9 2 1.0 
CP2 3.64 2 1.6 2 1.0 
CP3 4.49 2 2.5 2 1.0 
CP6 10.7 1 19.4 2 1.0 
[DNA] = DNA concentration. NA indicates samples do not require dilution. 
Supplementary Table 3 Unique Combinations of Illumina sequencing barcodes for CRC 
patients. 
Sample F primer R primer Sample F primer R primer 
M003 FPI5 RPI28 M032 FPI13 RPI22 
M004 FPI6 RPI27 M035 FPI13 RPI20 
M005 FPI5 RPI19 M036 FPI14 RPI21 
M006 FPI6 RPI20 M045 FPI14 RPI26 
M007 FPI7 RPI21 M047 FPI12 RPI24 
M010 FPI9 RPI19 M049 FPI13 RPI27 
M011 FPI8 RPI22 M051 FPI14 RPI28 
M013 FPI10 RPI22 M052 FPI15 RPI29 
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M014 FPI10 RPI20 M053 FPI16 RPI30 
M020 FPI5 RPI23 M054 FPI5 RPI27 
M022 FPI6 RPI30 M055 FPI6 RPI28 
M024 FPI9 RPI23 M056 FPI7 RPI29 
M025 FPI10 RPI26 M057 FPI8 RPI30 
M027 FPI10 RPI24 M058 FPI9 RPI24 
M028 FPI8 RPI23 M059 FPI13 RPI25 
M031 FPI12 RPI19 Roche FPI8 RPI25 
‘Roche’ indicates the healthy control – gDNA from Roche, Switzerland. 
 
Supplementary Figure 1 Confirmation of target PCR products in Sanger sequencing 
samples. 2.0% (w/v) Agarose gel run at 120V for 20 mins. Ladder is Maestrogen 1 Kb. Red 











C  D  
Supplementary Figure 2 Two additional Bioanalysis pools were prepared for patient M014 
to identify similar length amplicons. (A) and (B) are the Bioanalysis traces and (C) and (D) 
are the corresponding tables with the likely amplicons for each peak predicted. Those without 
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Supplementary Figure 3 Normal Bioanalysis Ladder. All Bioanalyses conducted in this 
project produced a normal trace for the ladder standard, such as the example presented here. 
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Supplementary Table 4 Replicate data used to calculate standard error mean (SEM) for 






















0.00 0.00 4.00 0.00 
12.58 14.52 7.26 
0.64 12.8 4.00 32.85 
0.25 5.00 4.00 12.83 
0.09 1.80 4.00 4.62 
23/03/2018 
0.00 0.00 2.60 0.00 
0 0 0 
0.00 0.00 2.60 0.00 
0.00 0.00 2.60 0.00 
0.00 0.00 2.60 0.00 
31/05/2018 
0.00 0.00 1.86 0.00 
8.83 17.66 8.83 
0.32 6.40 1.86 35.33 
0.00 0.00 1.86 0.00 
0.00 0.00 1.86 0.00 
16/11/2018 
0.50 10.0 2.00 51.33 
40.81 7.08 3.54 
0.37 7.40 2.00 37.99 
0.35 7.00 2.00 35.93 
0.37 7.40 2.00 37.99 
19/12/2018 
0.16 3.20 5.00 6.57 
7.39 2.86 1.43 
0.24 4.80 5.00 9.86 
0.09 1.80 5.00 3.70 
0.23 4.60 5.00 9.45 
07/01/2019 
0.37 7.40 1.25 60.78 
39.83 15.14 7.57 
0.22 4.40 1.25 36.14 
0.15 3.00 1.25 24.64 
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TYPE REF ALT Freq (%) 
M032 56435713 58358352 INDEL GAA G 78.36 
M004 56435160 58357799 INDEL AC A 74.45 
M013 56435160 58357799 INDEL AC A 42.71 
M047 56432355 58354994 INDEL TA T 11.32 
M052 
56434788 58357427 INDEL TC T 22.32 
56434793 58357432 INDEL TC T 21.93 
56434795 58357434 INDEL TC T 32.35 
M056 
56432251 58354890 INDEL AG A 5.61 
56436405 58359044 INDEL TA T 5.39 
56436411 58359050 INDEL TC T 32.69 
M057 
56432228 58354867 INDEL AG A 9.33 
56432251 58354890 INDEL AG A 8.75 






TYPE REF ALT Freq (%) 
M006 
56435080 58357719 SNV G C 22.82 
56438301 58360940 SNV G A 72.51 
56448433 58371072 SNV G A 10.63 
M028 56448433 58371072 SNV G A 9.23 
M049 56448297 58370936 SNV C T 49.05 
M051 56448433 58371072 SNV G A 10.38 
M054 56448433 58371072 SNV G A 11.17 
M055 
56448433 58371072 SNV G A 49.86 
56448297 58370936 SNV C T 43.56 
56436109 58358748 SNV C T 50.74 
56435885 58358524 SNV G T 9.72 
M011 
56435080 58357719 SNV G C 37.54 
56436109 58358748 SNV C T 66.8 
56448433 58371072 SNV G A 10.39 
M024 56448433 58371072 SNV G A 10.64 
M027 56448433 58371072 SNV G A 9.5 
M031 
56436109 58358748 SNV C T 56.16 
56448433 58371072 SNV G A 8.42 
M035 56448433 58371072 SNV G A 8.46 
M036 56448433 58371072 SNV G A 9.99 
M045 56448433 58371072 SNV G A 9.7 
M003 
56432363 58355002 SNV G A 7.57 
56432365 58355004 SNV G A 7.66 
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56432370 58355009 SNV A G 7.61 
56432373 58355012 SNV G A 98.63 
56435885 58358524 SNV G T 52.73 
56436109 58358748 SNV C T 55.22 
56448433 58371072 SNV G A 10.34 
M004 
56432363 58355002 SNV G A 6.02 
56432365 58355004 SNV G A 5.96 
56432370 58355009 SNV A G 5.88 
56435080 58357719 SNV G C 47.55 
56435885 58358524 SNV G T 53.33 
56448433 58371072 SNV G A 6.97 
M013 
56432363 58355002 SNV G A 5.69 
56432365 58355004 SNV G A 5.65 
56432370 58355009 SNV A G 5.68 
56435080 58357719 SNV G C 51.94 
56438301 58360940 SNV G A 51.08 
56448433 58371072 SNV G A 8.9 
M014 
56432363 58355002 SNV G A 7.29 
56432365 58355004 SNV G A 7 
56432370 58355009 SNV A G 7.31 
56435885 58358524 SNV G T 29.16 
56438301 58360940 SNV G A 67.28 
M020 
56432363 58355002 SNV G A 6.66 
56432365 58355004 SNV G A 6.63 
56432370 58355009 SNV A G 6.56 
56435080 58357719 SNV G C 36.71 
56435885 58358524 SNV G T 70.21 
56448433 58371072 SNV G A 9.88 
M022 
56432363 58355002 SNV G A 5.18 
56432365 58355004 SNV G A 5.18 
56432370 58355009 SNV A G 5.23 
56436044 58358683 SNV C T 48.22 
56448433 58371072 SNV G A 8.02 
M025 
56438301 58360940 SNV G A 45.67 
56448433 58371072 SNV G A 9.84 
M047 
56435080 58357719 SNV G C 51.14 
56448433 58371072 SNV G A 10.97 
M058 
56432363 58355002 SNV G A 6.9 
56432365 58355004 SNV G A 6.95 
56432370 58355009 SNV A G 6.91 
56435080 58357719 SNV G C 39.8 
56448433 58371072 SNV G A 9.65 
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M059 
56438301 58360940 SNV G A 72.86 
56448433 58371072 SNV G A 8.56 
M032 
56432363 58355002 SNV G A 5.53 
56432365 58355004 SNV G A 5.45 
56432370 58355009 SNV A G 5.44 
56438301 58360940 SNV G A 81.62 
56448433 58371072 SNV G A 9.67 
NEG 
56435080 58357719 SNV G C 11.04 
56435885 58358524 SNV G T 26.95 
56436109 58358748 SNV C T 12.66 
56438301 58360940 SNV G A 18.86 
56448297 58370936 SNV C T 12.22 
56448433 58371072 SNV G A 10.91 
Highlighted rows indicate mutations excluded due to likely experimental errors (orange) and those 
also present in the healthy control (grey). NEG = healthy control (gDNA from Roche, Switzerland).  
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